Vertex Pharmaceuticals (VRTX) EBT (2009 - 2026)

Vertex Pharmaceuticals' EBT history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, EBT rose 71.54% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $5.2 billion (up 1820.75% YoY), while the FY2025 annual figure was $4.6 billion, up 1768.49% from the prior year.
• EBT for Q1 2026 stood at $1.3 billion, down from $1.3 billion in the prior quarter.
• The five-year high for EBT was $1.3 billion in Q4 2025, with the low at -$3.4 billion in Q2 2024.
• The 5-year median for EBT is $1.2 billion (2023), against an average of $868.0 million.
• The sharpest annual moves came in 2022 and 2024: EBT jumped 2417.65% in 2022, then sank 391.97% in 2024.
• Vertex Pharmaceuticals' EBT stood at $1.1 billion in 2022, then climbed by 6.58% to $1.1 billion in 2023, then decreased by 0.97% to $1.1 billion in 2024, then rose by 17.11% to $1.3 billion in 2025, then dropped by 5.87% to $1.3 billion in 2026.
• Business Quant data shows VRTX's EBT at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.3 billion in Q3 2025.